Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 188

Similar articles for PubMed (Select 23529501)

1.

Mutations at the monomer-monomer interface away from the active site of influenza B virus neuraminidase reduces susceptibility to neuraminidase inhibitor drugs.

Fujisaki S, Imai M, Takashita E, Taniwaki T, Xu H, Kishida N, Yokoyama M, Sato H, Tashiro M, Odagiri T.

J Infect Chemother. 2013 Oct;19(5):891-5. doi: 10.1007/s10156-013-0589-6. Epub 2013 Mar 26.

PMID:
23529501
2.

A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.

Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T.

Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.

PMID:
23131559
3.

Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.

Dapat C, Kondo H, Dapat IC, Baranovich T, Suzuki Y, Shobugawa Y, Saito K, Saito R, Suzuki H.

Antiviral Res. 2013 Sep;99(3):261-9. doi: 10.1016/j.antiviral.2013.06.003. Epub 2013 Jun 17.

PMID:
23791870
4.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

5.

Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir.

Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y.

Antiviral Res. 2013 Mar;97(3):240-4. doi: 10.1016/j.antiviral.2012.12.013. Epub 2012 Dec 23.

PMID:
23267831
6.

Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season.

Okomo-Adhiambo M, Sleeman K, Lysén C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV.

Influenza Other Respir Viruses. 2013 Sep;7(5):645-58. doi: 10.1111/irv.12113. Epub 2013 Apr 10.

PMID:
23575174
7.

Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype.

Stoner TD, Krauss S, DuBois RM, Negovetich NJ, Stallknecht DE, Senne DA, Gramer MR, Swafford S, DeLiberto T, Govorkova EA, Webster RG.

J Virol. 2010 Oct;84(19):9800-9. doi: 10.1128/JVI.00296-10. Epub 2010 Jul 21.

8.

Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.

Yen HL, McKimm-Breschkin JL, Choy KT, Wong DD, Cheung PP, Zhou J, Ng IH, Zhu H, Webby RJ, Guan Y, Webster RG, Peiris JS.

MBio. 2013 Jul 16;4(4). pii: e00396-13. doi: 10.1128/mBio.00396-13.

9.

Human-like receptor specificity does not affect the neuraminidase-inhibitor susceptibility of H5N1 influenza viruses.

Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG.

PLoS Pathog. 2008 Apr 11;4(4):e1000043. doi: 10.1371/journal.ppat.1000043.

10.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
11.

Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.

Okomo-Adhiambo M, Nguyen HT, Sleeman K, Sheu TG, Deyde VM, Garten RJ, Xu X, Shaw MW, Klimov AI, Gubareva LV.

Antiviral Res. 2010 Feb;85(2):381-8. doi: 10.1016/j.antiviral.2009.11.005. Epub 2009 Nov 13.

PMID:
19917319
12.

Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus.

Pizzorno A, Abed Y, Bouhy X, Beaulieu E, Mallett C, Russell R, Boivin G.

Antimicrob Agents Chemother. 2012 Mar;56(3):1208-14. doi: 10.1128/AAC.05994-11. Epub 2011 Dec 27.

13.

Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

McSharry JJ, McDonough AC, Olson BA, Drusano GL.

Clin Diagn Lab Immunol. 2004 Jan;11(1):21-8.

14.

Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets.

Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA.

PLoS Pathog. 2010 May 27;6(5):e1000933. doi: 10.1371/journal.ppat.1000933.

15.

Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium.

Burnham AJ, Armstrong J, Lowen AC, Webster RG, Govorkova EA.

J Virol. 2015 Apr;89(8):4575-87. doi: 10.1128/JVI.02473-14. Epub 2015 Feb 11.

PMID:
25673705
16.

Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.

Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2008 Sep;52(9):3284-92. doi: 10.1128/AAC.00555-08. Epub 2008 Jul 14.

17.

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors.

Gubareva LV.

Virus Res. 2004 Jul;103(1-2):199-203.

PMID:
15163510
18.

In vitro selection of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.

Hatakeyama S, Ozawa M, Kawaoka Y.

Clin Microbiol Infect. 2011 Sep;17(9):1332-5. doi: 10.1111/j.1469-0691.2010.03313.x. Epub 2010 Jul 15.

19.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

20.

Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.

Hurt AC, Holien JK, Parker M, Kelso A, Barr IG.

J Virol. 2009 Oct;83(20):10366-73. doi: 10.1128/JVI.01200-09. Epub 2009 Jul 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk